Genetic Technologies (GENE)
(Delayed Data from NSDQ)
$0.92 USD
+0.12 (15.00%)
Updated Jul 15, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GENE 0.92 +0.12(15.00%)
Will GENE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GENE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for GENE
Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary
GeneType to Enter Canadian and New Zealand Markets
Cannabis Stock Gainers And Losers From June 27, 2024
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
GTG's GeneType identifies 79.5% of people tested at risk of serious disease